XML 63 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
License agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Feb. 28, 2018
USD ($)
Jan. 08, 2018
$ / shares
Dec. 31, 2017
USD ($)
[1]
Related Party Transaction [Line Items]                
Long term investment   $ 131,330   $ 131,330       $ 134,356
Research and development expense   298,089 $ 201,786 601,192 $ 609,706      
Unrealized (gain) loss on long term investments   (34,641) $ (19,574) (11,962) $ (25,388)      
Syros Pharmaceuticals, Inc.                
Related Party Transaction [Line Items]                
Number of program targets | item 7              
Upfront payment under license agreement $ 10,000              
Long term investment   $ 9,600   $ 9,600        
Ownership percentage (as a percent)   3.00%   3.00%        
Unrealized (gain) loss on long term investments   $ (2,600)   $ 600        
Syros Pharmaceuticals, Inc. | Stock purchase agreement                
Related Party Transaction [Line Items]                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.8              
Purchase price of common stock $ 10,000              
Per share price | $ / shares $ 12.61           $ 9.77  
Lock-up period 12 months              
Discount for lack of marketability $ 100              
Fair value of shares on the issuance date 7,600              
Long term investment 7,600              
Research and development expense $ 2,400              
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement                
Related Party Transaction [Line Items]                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.1              
Purchase price of common stock $ 1,400              
Per share price | $ / shares $ 9.55              
Long term investment           $ 1,400    
Syros Pharmaceuticals, Inc. | Maximum                
Related Party Transaction [Line Items]                
Target selection and option exercise fee payment $ 54,000              
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum                
Related Party Transaction [Line Items]                
Additional milestone payments under the license agreement 50,000              
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum                
Related Party Transaction [Line Items]                
Additional milestone payments under the license agreement $ 65,000              
[1] The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.